Repare Historical Balance Sheet

RPTX Stock

USD 3.32 0.17 5.40%

Trend analysis of Repare Therapeutics balance sheet accounts such as Total Stockholder Equity of 183 M, Other Liab of 2.9 M, Net Tangible Assets of 173 M or Property Plant And Equipment Net of 8.1 M provides information on Repare Therapeutics' total assets, liabilities, and equity, which is the actual value of Repare Therapeutics to its prevalent stockholders. By breaking down trends over time using Repare Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Repare Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Repare Therapeutics is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repare Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.

About Repare Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Repare Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Repare Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Repare Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Repare currently owns. An asset can also be divided into two categories, current and non-current.

Repare Therapeutics Balance Sheet Chart

At this time, Repare Therapeutics' Other Stockholder Equity is fairly stable compared to the past year. Total Liabilities is likely to rise to about 61.6 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 35.7 M in 2024.

Common Stock Shares Outstanding Total Assets Other Current Liab Total Current Liabilities Other Current Assets Common Stock

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Repare Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Repare Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Repare Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Repare Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most accounts from Repare Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Repare Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repare Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.At this time, Repare Therapeutics' Other Stockholder Equity is fairly stable compared to the past year. Total Liabilities is likely to rise to about 61.6 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 35.7 M in 2024.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	16.9M	19.5M	21.7M	11.7M
Total Assets	368.7M	364.1M	253.9M	267.7M

Other Current Liab Total Assets

Repare Therapeutics balance sheet Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Common Stock Shares Outstanding		0.92	0.83	0.78	0.85	0.51	0.86	0.88	-0.78	-0.84	0.56	0.8	0.86	0.62	0.53	0.91	0.7	0.87	0.07	0.87	0.88	0.73	0.68	0.85	0.9	0.92
Total Assets	0.92		0.84	0.8	0.98	0.68	0.95	0.98	-0.91	-0.82	0.47	0.93	0.95	0.5	0.68	1.0	0.61	0.93	-0.13	0.86	0.99	0.66	0.49	0.98	0.91	1.0
Other Current Liab	0.83	0.84		0.91	0.87	0.28	0.91	0.86	-0.61	-0.93	0.32	0.64	0.85	0.66	0.46	0.83	0.69	0.92	-0.43	0.94	0.84	0.84	0.24	0.87	0.94	0.84
Total Current Liabilities	0.78	0.8	0.91		0.8	0.16	0.8	0.79	-0.52	-0.82	0.0	0.55	0.73	0.46	0.31	0.8	0.52	0.82	-0.4	0.85	0.77	0.74	0.34	0.8	0.78	0.81
Total Stockholder Equity	0.85	0.98	0.87	0.8		0.67	0.98	0.96	-0.88	-0.82	0.42	0.9	0.94	0.49	0.66	0.98	0.61	0.94	-0.3	0.84	0.99	0.66	0.31	1.0	0.92	0.98
Other Liab	0.51	0.68	0.28	0.16	0.67		0.61	0.67	-0.91	-0.23	0.6	0.87	0.69	0.01	0.82	0.68	0.14	0.46	0.26	0.28	0.71	0.01	0.37	0.67	0.51	0.68
Net Tangible Assets	0.86	0.95	0.91	0.8	0.98	0.61		0.93	-0.83	-0.86	0.47	0.84	0.92	0.57	0.61	0.95	0.67	0.95	-0.33	0.87	0.97	0.72	0.26	0.98	0.96	0.95
Property Plant And Equipment Net	0.88	0.98	0.86	0.79	0.96	0.67	0.93		-0.91	-0.82	0.5	0.93	0.99	0.49	0.78	0.97	0.57	0.92	-0.15	0.87	0.97	0.64	0.46	0.96	0.92	0.97
Net Debt	-0.78	-0.91	-0.61	-0.52	-0.88	-0.91	-0.83	-0.91		0.56	-0.6	-0.99	-0.91	-0.25	-0.87	-0.91	-0.37	-0.74	-0.12	-0.62	-0.91	-0.34	-0.51	-0.88	-0.77	-0.91
Retained Earnings	-0.84	-0.82	-0.93	-0.82	-0.82	-0.23	-0.86	-0.82	0.56		-0.45	-0.63	-0.81	-0.86	-0.36	-0.81	-0.89	-0.96	0.41	-0.99	-0.81	-0.96	-0.27	-0.82	-0.93	-0.81
Accounts Payable	0.56	0.47	0.32	0.0	0.42	0.6	0.47	0.5	-0.6	-0.45		0.62	0.58	0.56	0.58	0.45	0.58	0.48	0.32	0.44	0.49	0.37	0.39	0.42	0.6	0.46
Cash	0.8	0.93	0.64	0.55	0.9	0.87	0.84	0.93	-0.99	-0.63	0.62		0.93	0.36	0.84	0.93	0.47	0.8	0.06	0.69	0.93	0.44	0.51	0.9	0.8	0.93
Non Current Assets Total	0.86	0.95	0.85	0.73	0.94	0.69	0.92	0.99	-0.91	-0.81	0.58	0.93		0.51	0.82	0.95	0.59	0.91	-0.13	0.87	0.95	0.64	0.44	0.94	0.94	0.95
Non Currrent Assets Other	0.62	0.5	0.66	0.46	0.49	0.01	0.57	0.49	-0.25	-0.86	0.56	0.36	0.51		0.07	0.48	0.98	0.75	-0.35	0.79	0.51	0.93	0.11	0.49	0.7	0.5
Other Assets	0.53	0.68	0.46	0.31	0.66	0.82	0.61	0.78	-0.87	-0.36	0.58	0.84	0.82	0.07		0.68	0.12	0.52	0.17	0.46	0.68	0.12	0.39	0.66	0.62	0.67
Cash And Short Term Investments	0.91	1.0	0.83	0.8	0.98	0.68	0.95	0.97	-0.91	-0.81	0.45	0.93	0.95	0.48	0.68		0.6	0.92	-0.13	0.85	0.99	0.65	0.5	0.98	0.9	1.0
Net Receivables	0.7	0.61	0.69	0.52	0.61	0.14	0.67	0.57	-0.37	-0.89	0.58	0.47	0.59	0.98	0.12	0.6		0.82	-0.34	0.82	0.63	0.94	0.16	0.61	0.76	0.61
Common Stock Total Equity	0.87	0.93	0.92	0.82	0.94	0.46	0.95	0.92	-0.74	-0.96	0.48	0.8	0.91	0.75	0.52	0.92	0.82		-0.38	0.96	0.94	0.87	0.28	0.94	0.96	0.93
Non Current Liabilities Total	0.07	-0.13	-0.43	-0.4	-0.3	0.26	-0.33	-0.15	-0.12	0.41	0.32	0.06	-0.13	-0.35	0.17	-0.13	-0.34	-0.38		-0.35	-0.21	-0.48	0.71	-0.3	-0.26	-0.13
Capital Surpluse	0.87	0.86	0.94	0.85	0.84	0.28	0.87	0.87	-0.62	-0.99	0.44	0.69	0.87	0.79	0.46	0.85	0.82	0.96	-0.35		0.84	0.92	0.34	0.84	0.93	0.85
Other Current Assets	0.88	0.99	0.84	0.77	0.99	0.71	0.97	0.97	-0.91	-0.81	0.49	0.93	0.95	0.51	0.68	0.99	0.63	0.94	-0.21	0.84		0.65	0.38	0.99	0.92	0.99
Other Stockholder Equity	0.73	0.66	0.84	0.74	0.66	0.01	0.72	0.64	-0.34	-0.96	0.37	0.44	0.64	0.93	0.12	0.65	0.94	0.87	-0.48	0.92	0.65		0.16	0.66	0.8	0.66
Total Liab	0.68	0.49	0.24	0.34	0.31	0.37	0.26	0.46	-0.51	-0.27	0.39	0.51	0.44	0.11	0.39	0.5	0.16	0.28	0.71	0.34	0.38	0.16		0.31	0.34	0.49
Net Invested Capital	0.85	0.98	0.87	0.8	1.0	0.67	0.98	0.96	-0.88	-0.82	0.42	0.9	0.94	0.49	0.66	0.98	0.61	0.94	-0.3	0.84	0.99	0.66	0.31		0.92	0.98
Property Plant And Equipment Gross	0.9	0.91	0.94	0.78	0.92	0.51	0.96	0.92	-0.77	-0.93	0.6	0.8	0.94	0.7	0.62	0.9	0.76	0.96	-0.26	0.93	0.92	0.8	0.34	0.92		0.91
Total Current Assets	0.92	1.0	0.84	0.81	0.98	0.68	0.95	0.97	-0.91	-0.81	0.46	0.93	0.95	0.5	0.67	1.0	0.61	0.93	-0.13	0.85	0.99	0.66	0.49	0.98	0.91

Click cells to compare fundamentals

Repare Therapeutics Account Relationship Matchups

Repare Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	36.7M	36.9M	37.8M	41.9M	42.1M	35.7M
Total Assets	102.7M	357.1M	368.7M	364.1M	253.9M	267.7M
Other Current Liab	4K	5.3M	16.9M	19.5M	21.7M	11.7M
Total Current Liabilities	4.2M	11.0M	35.1M	78.6M	39.1M	31.2M
Total Stockholder Equity	(46.1M)	286.8M	288.4M	279.5M	212.1M	183.0M
Other Liab	8.1M	55.9M	39.6M	2.7M	3.1M	2.9M
Net Tangible Assets	(46.1M)	286.8M	288.4M	279.5M	321.4M	173.0M
Property Plant And Equipment Net	3.4M	8.6M	13.1M	9.6M	7.5M	8.1M
Net Debt	(93.7M)	(322.2M)	(327.1M)	(154.1M)	(107.9M)	(113.3M)
Retained Earnings	(49.9M)	(103.4M)	(210.3M)	(239.3M)	(333.1M)	(316.5M)
Accounts Payable	2.1M	2.3M	2.3M	461K	2.4M	2.0M
Cash	94.8M	326.2M	334.4M	159.5M	111.3M	190.1M
Non Current Assets Total	4.1M	10.5M	17.3M	10.1M	10.2M	9.9M
Non Currrent Assets Other	567K	500K	586K	497K	2.7M	2.8M
Other Assets	699K	1.9M	4.2M	497K	571.6K	543.0K
Cash And Short Term Investments	94.8M	333.7M	341.9M	343.9M	223.6M	247.3M
Net Receivables	3.1M	6.2M	3.2M	4.3M	15.3M	16.1M
Liabilities And Stockholders Equity	102.7M	357.1M	368.7M	364.1M	253.9M	267.7M
Non Current Liabilities Total	144.6M	59.2M	45.2M	5.9M	2.7M	2.6M
Capital Lease Obligations	1.1M	4.0M	7.3M	5.4M	3.4M	3.9M
Other Current Assets	719K	6.7M	6.3M	5.7M	4.7M	4.5M
Other Stockholder Equity	3.8M	5.9M	18.0M	37.2M	61.8M	64.9M
Total Liab	148.8M	70.3M	80.3M	84.6M	41.8M	61.6M
Net Invested Capital	(46.1M)	286.8M	288.4M	279.5M	212.1M	183.0M
Property Plant And Equipment Gross	3.4M	8.6M	13.1M	9.6M	14.8M	9.4M
Total Current Assets	98.6M	346.6M	351.4M	354.0M	243.7M	257.8M
Net Working Capital	94.3M	335.5M	316.3M	275.4M	204.6M	226.7M
Property Plant Equipment	3.4M	8.6M	5.6M	9.6M	11.0M	6.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Repare Historical Balance Sheet

About Repare Balance Sheet Analysis

Repare Therapeutics Balance Sheet Chart

Common Stock Shares Outstanding

Total Assets

Total Current Liabilities

Other Current Assets

Repare Therapeutics balance sheet Correlations

Repare Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Repare Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for Repare Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Current Assets	+ 0.99	Total Assets
Other Current Assets	+ 0.99	Total Stockholder Equity

Capital Surpluse	- 0.99	Retained Earnings
Cash	- 0.99	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Common Stock Total Equity	- 0.96	Retained Earnings
Property Plant And Equipment Gross	- 0.93	Retained Earnings
Retained Earnings	- 0.93	Other Current Liab